8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – September 26, 2007

________________________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

_____________________

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

610-594-3319

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Kthelman/SEC drafts/Form 8-K - September 2007CL King Conference

Item 7.01 Regulation FD Disclosure

On September 11, 2007, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William J. Federici, Chief Financial Officer, will make a presentation at the UBS 2007 Global Life Sciences Conference at the Grand Hyatt in New York City on Wednesday, September 26, 2007 at 9:30 a.m. Eastern Time.

A copy of the Company’s presentation from the conference will be available for 30 days through the Investor link at the Company’s website, http.//www.westpharma.com., and is also attached hereto as Exhibit 99.1. A copy of the press release is attached hereto as Exhibit 99.2. Both Exhibits are incorporated herein by reference.

The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01			Financial Statements and Exhibits
	(d)	Exhibits
		Exhibit #		Description
		99.1		West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation).
		99.2		West Pharmaceutical Services, Inc. Press Release, dated September 11, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

September 26, 2007

EX-99

Donald E. Morel, Jr., Ph.D.

Chairman and Chief Executive Officer

West Pharmaceutical Services

William J. Federici

Vice President & Chief Financial Officer

West Pharmaceutical Services

NYSE: WST

westpharma.com

UBS

Global Life Sciences Conference

September 24 - 27, 2007

         Certain statements contained in this presentation and certain statements that may be made by management of the
Company orally during this presentation contains some forward-looking statements that set forth anticipated results based on
management’s plans and assumptions.  Such statements give our current expectations or forecasts of future events – they do
not relate strictly to historical or current facts. We have tried, wherever possible, to identify such statements by using words
such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and terms of similar meaning in
connection with any discussion of future operating or financial performance or condition.

       We cannot guarantee that any forward-looking statement will be realized. If known or unknown risks or uncertainties
materialize, or if underlying assumptions are inaccurate, actual results could differ materially from past results and those
expressed or implied in any forward-looking statement.  You should bear this in mind as you consider forward-looking
statements. We cannot predict or identify all such risks and uncertainties, but factors that could cause the actual results to
differ materially from expected and historical results include the following: Sales demand; the timing, regulatory approval and
commercial success of customers’ products incorporating our products and services, including specifically, the Exubera®
Inhalation-Powder insulin device; customers’ changes to inventory requirements and manufacturing plans that alter existing
orders or ordering patterns for our products; our ability to pass raw-material cost increases on to customers through price
increases; maintaining or improving production efficiencies and overhead absorption; physical limits on manufacturing
capacity that may limit our ability to satisfy anticipated demand; the timeliness and effects of capacity expansions, including
the effects of delays associated with construction, availability and price of capital goods, and necessary internal, governmental
and customer approvals; the availability of labor to meet increased demand; competition from other providers; the timely and
successful negotiations of sales contracts with four of the Company’s largest customers during the second half of 2007,  
average profitability, or mix, of products sold in any reporting period; financial performance of unconsolidated affiliates;
strength of the U.S. dollar in relation to other currencies, particularly the Euro, UK Pound, Danish Krone, Japanese Yen and
Singapore Dollar; changing interest rates and investment returns that can affect the Company’s cost of funds and return on
invested funds; interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the availability
of raw materials and key bought-in components and finished products; raw-material price escalation, particularly petroleum-
based raw materials, and energy costs; availability and pricing of raw materials that may be affected by vendor concerns with
exposure to product-related liability; and, changes in tax law or loss of beneficial tax incentives.

       We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future
events or otherwise.     

Safe Harbor Statement

Founded in 1923

HQ in Lionville, PA

Corporate Background

Corporate Profile

World’s premier manufacturer
of components and systems
for injectable drug delivery

Closure systems and prefillable
syringe components

Components for disposable
systems

Devices and device sub-
assemblies

2006 sales $913M

Market cap $1.4 billion

Diverse Customer Base

Company Estimated Market Share: 70% in Pharma; 70% in Device; 95% in Biotech

Global
Presence

32 manufacturing sites

34 sales offices

5 technical centers

Partner locations

Future China plants

6,000 employees

Key Company Developments

FY 2001 - 2005

New management team

Divestiture of non-core businesses

Focus returned to injectable packaging and delivery

Increased capital expenditures and capacity build in Europe

Strategic acquisitions

Strong revenue and profit growth

FY 2006

Debt restructuring

Integration of acquisitions

China initiative launched

Second European expansion

Strongest operating year in company history

FY 2007

Daikyo agreements extended to 2017

Issued $161.5 million of 4% convertible junior sub debt due 2047

Announced stock buy-back of up to 1 million shares

(in millions)

Strong Sales Growth 2002-2006

$227

           Acquisitions

          Core Business

$107

Segment Revenues - 2006

Geographic Sales Mix - 2006

Corporate Growth Strategy

Pharmaceutical Systems Segment

Market segmentation

Generate maximum value from key growth drivers

New product innovation

Lean manufacturing

Geographic expansion

Strategic acquisitions

Tech Group Segment

Leverage West customer base to build market share in multi-
material/multi-component systems for drug administration

Expand proprietary product portfolio through innovation and
strategic technology acquisitions

Market Dynamics Support West’s
Continued Growth

Increasing number of patients with chronic illnesses such as diabetes
and cancer

Increasing demand for biologics 2006 Market: $56B*

Biologic drugs represent the fastest growing segment of the injectable pharma
market (13% CAGR projected through 2010)*

Injectables currently account for ~15% of the global drug delivery market^

Point of care shift: Hospital   Specialty Clinic   Home

Parenteral dosage form migration

*Source: Datamonitor

^Source: Arrowhead Publishers

Dosage Form Migration

Reconstitution
System

Vial – Stopper – Seal

Prefillable Syringe

Ampoule

Auto-injectors

Market Dynamics Support West’s
Continued Growth

Increasing number of patients with chronic illnesses such as diabetes
and cancer

Increasing demand for biologics 2006 Market: $56B*

Biologic drugs represent the fastest growing segment of the injectable pharma
market (13% CAGR projected through 2010)*

Injectables currently account for ~15% of the global drug delivery market^

Point of care shift: Hospital   Specialty Clinic   Home

Parenteral dosage form migration

Emergence of delivery systems that combine the primary drug container and delivery
platform

*Source: Datamonitor

^Source: Arrowhead Publishers

Convergence of Primary Containers and
Delivery Systems

Auto Injectors

with Cartridges

Components for
Pen System Applications

West’s Competitive Advantage

Unmatched experience/expertise: drug material interface

Ability to source components from multiple locations globally

Protected IP: West’s components and systems

Regulatory barrier to entry:  NDA and ANDA filing must include reference
to all packaging/components in contact with the drug

1.

West Drug Master File (DMF) 1546 is confidential

2.

West DMF includes functionality data (multi-year studies)

3.

All primary package changes require new stability/functionality
studies for new filing

Engineering expertise in high-volume manufacturing and assembly

Strategic Objectives

Continue to maintain market leadership position in the
biotechnology market

Components for

Prefillable Syringes

* FluroTec technology is licensed from Daikyo Seiko, Ltd.

FluroTec^* and

BarrierCoatings

Westar^®
Processing

Strategic Objectives

Expand position in the insulin/diabetes care segment

Components for
Pen System Applications

Components for

Traditional System
Applications

Devices

Strategic Objectives

Aggressively expand IP position via innovation and
selective acquisitions

Anti-Counterfeiting
Closures

Reconstitution Systems

Daikyo Crystal Zenith*
Systems

* Daikyo Crystal Zenith technology is licensed from Daikyo Seiko, Ltd.

Strategic Objectives

Build manufacturing capabilities to meet market growth

Create financial flexibility through conservative balance
sheet management

Strategic Objectives

Prior Years’ Results
($M except per share)

$46.0

$61.5

Income from Continuing Operations

$1.41

$1.93

E.P.S. Continuing Operations –
Non-GAAP

$73.4

$101.0

Operating Profit

$120.3

$155.9

SG&A

    27.7%

28.7%

Gross Margin

   $699.7

   $913.3

Net Sales

    2005

     2006

2006 E.P.S. continuing operations – Non-GAAP excludes a $0.12 charge related to the refinancing of debt obligations
and a $0.02 favorable tax benefit related to the settlement of a prior year tax claim.

June 30, 2007 Year-to-Date Results($M except per share)

$35.0

$53.0

Income from Continuing
Operations

$1.15

$1.45

Non-GAAP E.P.S. from
Continuing Operations

$60.3

$74.4

Operating Profit

$71.2

$75.2

SG&A

    30%

30%

Gross Margin

  $463.0

$521.3

Net Sales

2006

   2007

Non-GAAP EPS excludes 6 cents of discrete tax benefits from 2007 reported results and excludes a 12 cent charge for debt refinancing and a 2 cent
favorable tax benefit from 2006 reported results.

Capital Management

($M)

$90.3

$130.0

Full Year Capital Expenditures

31.1%

29.4%

     Net Debt to Total Capital

$419.3

$499.1

Total Equity & Minority Int.

$236.3

$384.7

Total Debt

$47.1

$177.3

Cash

     12/31/2006

    6/30/2007

Manage core business growth

Segmentation/therapeutic category management

Improve Tech Group profit margins

Shift product mix: focus on healthcare and proprietary products

Maximize global capacity utilization

Execute on European capacity expansion and China initiative

Execute innovation programs

Operating Priorities

2007 Guidance – as of August 2, 2007

Revenues – approximately $1.0 billion

Estimated consolidated gross margin of 29%

Fully diluted earnings per share of $2.27 to $2.37

Excluding 6 cents discrete tax benefits

R&D spending increased to $17 million

Capital spending of $120 to $130 million

Summary

2007 on pace for approximately 20% growth in EPS

West’s competitive advantages uniquely position the
Company to capitalize on growth drivers in key market
segments

Global manufacturing capability

Solid balance sheet

Management incentives closely tied to growth in
shareholder value

Strong corporate governance (ranked #8 in Russell 3000)

Donald E. Morel, Jr., Ph.D.

Chairman and Chief Executive Officer

West Pharmaceutical Services

William J. Federici

Vice President & Chief Financial Officer

West Pharmaceutical Services

NYSE: WST

westpharma.com

UBS

Global Life Sciences Conference

September 24 - 27, 2007

EX-99

Contacts: West Pharmaceutical Services, Inc. Michael A. Anderson Vice President and Treasurer (610) 594-3345 Investors and Financial Media: Financial Dynamics Evan Smith / Theresa Kelleher (212) 850-5600 wst@fd.com

WEST PHARMACEUTICAL SERVICES TO PRESENT AT UPCOMING CONFERENCES

Exhibit 99.2

LIONVILLE, PA, September 11, 2007 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced that management will be presenting at two upcoming conferences:

• The CL King 2007 Best Ideas Conference at the Omni Berkshire Place Hotel in New York City. The presentation is scheduled for 2:45pm on Tuesday, September 18, 2007. An audio webcast will also be available live at that time. The replay of the audio portion will be available within 24 hours after the actual presentation time and will be available until for 90 days.

• The 2007 UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City. The presentation is scheduled for 9:30am on Wednesday, September 26, 2007. A live audio webcast and a copy of the presentation will also be available live at that time. The replay of the audio portion will be available within 3 hours after the actual presentation time and will be available for 30 days.

The audio webcasts and copies of the corporate presentation documents will be posted on the investor link of the Company’s website at www.westpharma.com.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is the world's premier manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. West's customers include the world's leading pharmaceutical, biotechnology, generic drug and medical device producers. Headquartered in Lionville, Pennsylvania, West Pharmaceutical Services supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at http://www.westpharma.com.